Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 31;38(1):3–15. doi: 10.3892/ijmm.2016.2620

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Katoh et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Selection of fibroblast growth factor receptor (FGFR) inhibitor for precision medicine. (A) Classification of FGFR inhibitors based on substrate specificities. ^*, FIIN-2 is for experimental use only. ^**, Severe adverse effects of ponatinib have been reported in patients with chronic myeloid leukemia. (B) Flow-chart for the choice of FGFR inhibitor in clinic. MPN, myeloproliferative neoplasm; Amp, gene amplification; OverE, overexpression; Fus, fusion. FGFR1/2/3 inhibitors and pan-FGFR inhibitors are applicable for human cancer with genetic alteration in FGFR1, FGFR2 or FGFR3. FGFR1/2/3 inhibitors are not the choice for patients with heart diseases, whereas pan-FGFR inhibitors are not the choice for patients with liver dysfunction. FGFR4 inhibitor is applicable for HCC with genetic alteration in FGF19.